<DOC>
	<DOCNO>NCT02755753</DOCNO>
	<brief_summary>The purpose study evaluate whether Rebamipide facilitate heal inflame mucosa adjuvant regimen erosive reflux esophagitis ( ERE ) .</brief_summary>
	<brief_title>A Study Evaluate REbamiPide Adjuvant Regimen Heal erosIve Reflux Esophagitis</brief_title>
	<detailed_description>1 . To evaluate whether Rebamipide facilitate heal inflame mucosa adjuvant regimen erosive reflux esophagitis patient 2 . To evaluate safety rebamipide adjuvant regimen erosive reflux esophagitis ( ERE )</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis , Peptic</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>1 . Male/female patient age 20 70 time write informed consent . 2 . Subjects diagnose Erosive Reflux Esophagitis ( ERE ) use Los Angeles ( LA ) classification grade A~D , confirm endoscopy . 3 . The subject regardless presence ERE symptom ( i.e. , symptomatic ERE asymptomatic ERE ) . For symptomatic ERE , subject must one symptoms following : acid regurgitation , heartburn , epigastric pain , cough , hoarseness , globus pharyngis , atypical chest pain . 4 . Subjects consent participate clinical study signing inform consent form . 1 . Patients know hypersensitivity component Lanston® and/or Mucosta® formulation . 2 . Other concurrent organic upper gastroesophageal disease endoscopy ( i.e. , druginduced esophagitis , viral esophagitis , MalloryWeiss syndrome , peptic ulcer disease , malignancy ) patient diagnose Barrett 's esophagus . 3 . History abdominal surgery affect gastrointestinal motility ( except appendectomy hysterectomy ) . 4 . History upper gastrointestinal bleeding obstruction . 5 . Patients administrate drug affect efficacy study regimen ( proton pump inhibitor , revaprazan , prokinetics , H2blockers , etc . ) within 2 week ( however , 4 week PPIs ) prior enrollment and/or require NSAIDs , anticoagulant , anticholinergic , prostaglandin E , corticosteroid , antidepressant treatment study period . 6 . History pancreatobiliary disease ( except asymptomatic gallbladder stone ) , inflammatory bowel disease , cirrhotic liver disease , chronic kidney disease . 7 . Pregnant , nursing , childbearing potential woman unwilling effective contraception ; example , oral contraceptive , hormonal method , placement intrauterine device ( IUD ) intrauterine system ( IUS ) , barrier method ( i.e. , condom occlusive cap spermicidal foam/gel/film/cream/suppository ) , male sterilization , true abstinence . 8 . History psychological disorder , alcoholic , drug abuser . 9 . Blood test result hemoglobin ( Hb ) ≤ 10.0 g/dL , platelet ≤ 50,000 /µL , total WBCs ≤ 4,000/µL ≥ 10,000/µL , serum test result show level AST , ALT , ALP , BUN , creatinine exceed twice normal range respective institution . 10 . Patients previously underwent another clinical survey within 4 week . 11 . History major medical disease affect general condition patient deem eligible study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Rebamipide</keyword>
</DOC>